Cargando…

Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19)

BACKGROUND: While the 2019 novel coronavirus disease (COVID-19) outbreak has been largely kept under control in China, it remains a global pandemic, and the source, transmission route, and treatments of SARS-COV-2 are still being investigated. Here, we summarized the clinical features, diagnosis, tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Kebin, Xiong, Weining, Zhou, Xin, Li, Huiping, Zheng, Junhua, Xu, Jinfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867930/
https://www.ncbi.nlm.nih.gov/pubmed/33569465
http://dx.doi.org/10.21037/atm-21-236
_version_ 1783648376454119424
author Cheng, Kebin
Xiong, Weining
Zhou, Xin
Li, Huiping
Zheng, Junhua
Xu, Jinfu
author_facet Cheng, Kebin
Xiong, Weining
Zhou, Xin
Li, Huiping
Zheng, Junhua
Xu, Jinfu
author_sort Cheng, Kebin
collection PubMed
description BACKGROUND: While the 2019 novel coronavirus disease (COVID-19) outbreak has been largely kept under control in China, it remains a global pandemic, and the source, transmission route, and treatments of SARS-COV-2 are still being investigated. Here, we summarized the clinical features, diagnosis, treatment, and prognosis of COVID-19 patients based on our clinical practice. METHODS: The clinical and imaging findings, treatments, and follow-up data of 471 patients with COVID-19 who were discharged from the Wuhan Jinyintan Hospital prior to February 6, 2020, were retrospectively analyzed. RESULTS: Among these patients, there were 2 mild cases, 282 moderate cases, 181 severe cases, and 6 critical cases. There were 250 males and 221 females aged 17 to 90 years. The median age was 54 years in the severe/critical group, which was significantly older than in the mild/moderate group (P<0.05). 44.59% of them had one or more underlying diseases. The most common symptoms were fever, cough, expectoration, and dyspnea. The median body temperature in the severe/critical group was 39°C, which was significantly higher than in the mild/moderate group (P<0.05). The incidences of lymphopenia and CD4(+) T lymphocytopenia were 53.5% and 41.86%, respectively. Ground-glass opacity and small patchy shadows were the most common findings on chest computed tomography (CT). Compared with the mild/moderate group, the severe/critical group showed higher proportions of severe lymphocytopenia and CD4(+) T lymphocytopenia, along with more ground-glass shadows and large-scale consolidation. After anti-infection, oxygen therapy, and symptomatic support, lymphocytes and CD4(+) T lymphocytes were markedly increased, all patients were discharged. The median time of nucleic acid conversion and hospital stay were 9 and 12 days, respectively, which were significantly longer in the severe/critical group than in the mild/moderate group. Of the 390 cases followed, only 19 were hospitalized again due to other diseases. All patients recovered well from COVID-19, with negative nucleic acid test results. CONCLUSIONS: Lymphocytopenia and CD4(+) T lymphocytopenia were found to be associated with COVID-19 and thus may be important indicators in evaluating the severity and prognosis. Multidisciplinary management including antiviral treatment, immune regulation, and symptomatic support is effective, and yields a low recurrence rate.
format Online
Article
Text
id pubmed-7867930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-78679302021-02-09 Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19) Cheng, Kebin Xiong, Weining Zhou, Xin Li, Huiping Zheng, Junhua Xu, Jinfu Ann Transl Med Original Article BACKGROUND: While the 2019 novel coronavirus disease (COVID-19) outbreak has been largely kept under control in China, it remains a global pandemic, and the source, transmission route, and treatments of SARS-COV-2 are still being investigated. Here, we summarized the clinical features, diagnosis, treatment, and prognosis of COVID-19 patients based on our clinical practice. METHODS: The clinical and imaging findings, treatments, and follow-up data of 471 patients with COVID-19 who were discharged from the Wuhan Jinyintan Hospital prior to February 6, 2020, were retrospectively analyzed. RESULTS: Among these patients, there were 2 mild cases, 282 moderate cases, 181 severe cases, and 6 critical cases. There were 250 males and 221 females aged 17 to 90 years. The median age was 54 years in the severe/critical group, which was significantly older than in the mild/moderate group (P<0.05). 44.59% of them had one or more underlying diseases. The most common symptoms were fever, cough, expectoration, and dyspnea. The median body temperature in the severe/critical group was 39°C, which was significantly higher than in the mild/moderate group (P<0.05). The incidences of lymphopenia and CD4(+) T lymphocytopenia were 53.5% and 41.86%, respectively. Ground-glass opacity and small patchy shadows were the most common findings on chest computed tomography (CT). Compared with the mild/moderate group, the severe/critical group showed higher proportions of severe lymphocytopenia and CD4(+) T lymphocytopenia, along with more ground-glass shadows and large-scale consolidation. After anti-infection, oxygen therapy, and symptomatic support, lymphocytes and CD4(+) T lymphocytes were markedly increased, all patients were discharged. The median time of nucleic acid conversion and hospital stay were 9 and 12 days, respectively, which were significantly longer in the severe/critical group than in the mild/moderate group. Of the 390 cases followed, only 19 were hospitalized again due to other diseases. All patients recovered well from COVID-19, with negative nucleic acid test results. CONCLUSIONS: Lymphocytopenia and CD4(+) T lymphocytopenia were found to be associated with COVID-19 and thus may be important indicators in evaluating the severity and prognosis. Multidisciplinary management including antiviral treatment, immune regulation, and symptomatic support is effective, and yields a low recurrence rate. AME Publishing Company 2021-01 /pmc/articles/PMC7867930/ /pubmed/33569465 http://dx.doi.org/10.21037/atm-21-236 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Cheng, Kebin
Xiong, Weining
Zhou, Xin
Li, Huiping
Zheng, Junhua
Xu, Jinfu
Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19)
title Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19)
title_full Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19)
title_fullStr Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19)
title_full_unstemmed Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19)
title_short Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19)
title_sort diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (covid-19)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867930/
https://www.ncbi.nlm.nih.gov/pubmed/33569465
http://dx.doi.org/10.21037/atm-21-236
work_keys_str_mv AT chengkebin diagnosisandtreatmentof471patientswith2019novelcoronavirusdiseasecovid19
AT xiongweining diagnosisandtreatmentof471patientswith2019novelcoronavirusdiseasecovid19
AT zhouxin diagnosisandtreatmentof471patientswith2019novelcoronavirusdiseasecovid19
AT lihuiping diagnosisandtreatmentof471patientswith2019novelcoronavirusdiseasecovid19
AT zhengjunhua diagnosisandtreatmentof471patientswith2019novelcoronavirusdiseasecovid19
AT xujinfu diagnosisandtreatmentof471patientswith2019novelcoronavirusdiseasecovid19